Arcus Biosciences Price to Free Cash Flow Ratio 2017-2022 | RCUS

Historical price to free cash flow ratio values for Arcus Biosciences (RCUS) since 2017. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Arcus Biosciences Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2022-05-27 19.19 3.01
2022-03-31 31.56 $6.37 4.95
2021-12-31 40.47 $-3.82 0.00
2021-09-30 34.87 $-3.49 0.00
2021-06-30 27.46 $0.97 28.34
2021-03-31 28.08 $1.64 17.11
2020-12-31 25.96 $1.97 13.15
2020-09-30 17.14 $2.22 7.71
2020-06-30 24.74 $-2.00 0.00
2020-03-31 13.88 $-2.03 0.00
2019-12-31 10.10 $-1.72 0.00
2019-09-30 9.10 $-1.93 0.00
2019-06-30 7.95 $-1.59 0.00
2019-03-31 12.49 $-0.24 0.00
2018-12-31 10.77 $-1.35 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.305B $0.383B
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $165.194B 10.05
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.361B 16.35
Biohaven Pharmaceutical Holding (BHVN) United States $10.098B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.208B 0.00
Emergent Biosolutions (EBS) United States $1.617B 6.92
Myovant Sciences (MYOV) United Kingdom $0.956B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.500B 0.00
Zymeworks (ZYME) Canada $0.368B 0.00
Gelesis Holdings (GLS) United States $0.349B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.108B 22.10
SQZ Biotechnologies (SQZ) United States $0.097B 0.00